SYNERGISTIC ENHANCEMENT OF CISPLATIN CYTOTOXICITY BY SN-38, AN ACTIVE METABOLITE OF CPT-11, FOR CISPLATIN-RESISTANT HELA-CELLS
SYNERGISTIC ENHANCEMENT OF CISPLATIN CYTOTOXICITY BY SN-38, AN ACTIVE METABOLITE OF CPT-11, FOR CISPLATIN-RESISTANT HELA-CELLS
复制标题
DOI：
10.1111/j.1349-7006.1994.tb02976.x
复制
发表时间：
1994-09-01
期刊：
影响因子：
--
通讯作者：
TERAKAWA, N
中科院分区：
文献类型：
--
作者：
MINAGAWA, Y;KIGAWA, J;TERAKAWA, N
A cisplatin (cis-diamminedichloroplatinum (II); CDDP)-resistant HeLa cell line (HeLa/CDDP cells), which showed more than 8-fold resistance to CDDP compared to the parent cells, was newly established for this study. HeLa/CDDP cells accumulated 50% less platinum than the parent cells. There was no difference in intracellular glutathione (GSH) content between the parent and HeLa/CDDP cells. The dose modification factor by DL-buthionine-S,R-sulfoximine (BSO) pretreatment was similar in both cell lines. HeLa/CDDP cells had cross-resistance to diammine(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA), (cis-diammine(glycolato)platinum (254-S), but not to (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II) (DWA2114R), adriamycin, or VP-16. HeLa/CDDP cells showed a collateral sensitivity to 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11). Furthermore, isobologram analysis indicated synergistic interaction of CDDP and SN-38 only for HeLa/CDDP cells. The present study suggests that combination therapy with CDDP and CPT-11 may be potentially useful in the treatment of some patients with CDDP-resistant cancer.
